Sunday, November 8, 2026

USD/EUR Slides By 2% In The Last 21 Sessions

USD/EUR Slides By 2% In The Last 21 Sessions

(VIANEWS) - USD/EUR (USDEUR) has been up by 2.29% for the last 21 sessions. At 18:10 EST on Monday, 17 April, USD/EUR (USDEUR) is $0.92.

USD/EUR's yearly highs and lows, it's 1.34% up from its 52-week low and 12.707% down from its 52-week high.

News about

  • Usd/jpy traces on sluggish yields below 134.00 even as boj vs. fed divergence regains attention. According to FXStreet on Monday, 17 April, "Not only a lack of major data/events but mixed catalysts and sluggish yields also challenge the USD/JPY pair traders of late.", "Recently, the geopolitical challenges emanating from China, due to its eagerness to collaborate with Russia on global and regional security, as well as tussles with the US over Taiwan, prod the market sentiment and weigh on the USD/JPY pair."
  • Usd/jpy eases from over one-month peak, trades with modest gains just below 134.00. According to FXStreet on Monday, 17 April, "This, along with the US bond yields, should influence the USD price dynamics and provide some impetus to the USD/JPY pair. ", "Expectations that the Federal Reserve (Fed) will pause its rate-hiking cycle, sooner rather than later, fail to assist the US Dollar (USD) to capitalize on its recovery move from a one-year low, which, in turn, acts as a headwind for the USD/JPY pair. "
  • Usd/jpy price analysis: gains momentum on rising US treasury bond yields. According to FXStreet on Monday, 17 April, "Conversely, if the USD/JPY retraces, the first support would be 100-day EMA at 134.00. ", "The USD/JPY extended its gains past the last week's high of 134.04, and it's aiming to challenge a break above January 6 high at 134.77. "

More news about USD/EUR (USDEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com